Growth Signals: Decoding Business Momentum

$8.4M in Home4Good grants will fund 110 programs in DE, PA, and WV, offering a lifeline as housing insecurity deepens across the region.

As biotech and pharma risks evolve, Verist Inc. launches tailored coverage, aiming to redefine insurance with a high-touch, data-driven service model.

A South Korean AI firm is transforming Wall Street and the insurance industry with strategic funding from AWS and a unique human-centric technology.

Can-Fite BioPharma eyes key 2026 data readouts for its late-stage oral drugs targeting advanced liver cancer, psoriasis, and other unmet medical needs.

A music legend's donation fuels a new model for equitable recovery, helping Black communities in LA rebuild not just homes, but generational wealth.

A family transformed personal loss into a record-breaking charity. We decode the growth signals behind a grassroots toy drive that’s scaling across Canada.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

Focus Financial Partners names growth architect Adam Birenbaum its next CEO, signaling a strategic shift toward deeper integration and accelerated expansion.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

A 91% strike vote at a NS nursing home reveals deep wage gaps and a staffing crisis, placing the future of elder care at a perilous crossroads.

As climate disasters escalate, a major insurer is shifting from payouts to prevention. We decode this signal and its implications for the future of risk.

Ontario's new FAST program speeds access to cancer drugs like Scemblix, challenging Canada's slow reimbursement system. Is this a new national blueprint?

Regenerative Patch Technologies advances its stem cell therapy for dry AMD, signaling a potential shift from merely slowing blindness to actively improving vision.

Eli Lilly's takeover of Adverum signals a major push into ocular gene therapy. Can a one-time injection for vision loss disrupt a multi-billion dollar market?

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.